• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Takeda, leon-nanodrugs ink feasibility testing deal for reformulated drug

July 17, 2018 By Sarah Faulkner

Takeda, leon-nanodrugs dealleon-nanodrugs said today that Takeda (TYO:4502) tapped its MicroJet Reactor technology as part of a feasibility study that could result in the reformulation of one of Takeda’s pipeline products.

Using leon’s nanotechnology platform, the companies plan to boost the solubility, bioavailability and stability of one of Takeda’s pipeline products. Positive results from the feasibility study could yield a “long-term collaboration” between the two groups, leon said.

The company touted its MJR technology as offering reformulation options that optimize an active pharmaceutical ingredient’s bioavailability and solubility. Leon described its platform as a one-step, continuous precipitation approach that is cost-effective and scalable.

“We are very pleased and proud that Takeda selected our MJR technology for a feasibility assessment with one of their compounds in development,” leon CEO Michael Mehler said in prepared remarks. “It is a major milestone for our company to win Takeda, a globally leading pharmaceutical company, as a partner and we look forward to this collaboration with the goal to contributing to bring valuable new medicines to patients worldwide.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Nanoparticles, Pharmaceuticals, Wall Street Beat Tagged With: leon-nanodrugs GmbH, Takeda Pharmaceutical Co

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS